FDA moves to fast-track review of 3 psychedelic drug studies
Left(0)
Center(1)
Right(3)
Just the NewsCApr 24, 12:00 AM
FDA approves three fast-track studies of psychedelic drugs to treat PTSD, depression
The FDA did not specify what companies will conduct the research, but two of the companies are studying psilocybin. The third company is studying methylone, which is similar to the psychedelic MDMA, a
Washington TimesCApr 24, 5:33 PM
5 questions about the FDA's fast-track push for psychedelic treatments
The Food and Drug Administration awarded priority review vouchers to three companies developing psychedelic-based treatments for mental health conditions -- two studying psilocybin for hard-to-treat d
ReasonAApr 24, 9:05 PM
The FDA Fast-Tracks Its Review of Psilocybin and Methylone, 2 Promising Psychedelics
The agency issued "national priority vouchers" for the two drugs six days after President Donald Trump promised to facilitate approval of psychedelic therapies.
Get this analysis in your inbox
The Daily Spectrum: one email, three perspectives on the day's biggest stories.
Free forever. Unsubscribe anytime. No spam.